Drug Trial Radar · NCT04508140
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Jun 17, 2020
Primary completion
Dec 2, 2022
Study completion Dec 2, 2022
Sponsor
- Lead sponsor
- Highlight TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open, single arm, multicenter phase 2 trial in which BO-112 will be administered intratumorally in combination with intravenous pembrolizumab in patients with liver metastasis from colorectal, gastric or gastroesophageal junction cancers. The objective is to reverse the primary resistance that a subgroup of patients from these tumors having microsatellite stability present to the PD-1 inhibitors. Treatment will be administered every 3 weeks, with the exception of the first cycle, in which BO-112 will be also administered on D8, for up to 2 years. The primary objective is overall response rate based on RECIST 1.1 and safety, specifically referred to treatment emergent adverse events (TEAEs) with severity ≥ Grade 3 related to the study treatment (NCI-CTCAE v 5.0). The secondary endpoints include other efficacy endpoints (duration of response, disease control rate, progression-free survival, overall survival at 6 months, all based on RECIST 1.1, and overall response rate based on a specific tumor assessment criteria to evaluate the response to immunotherapies, IRECIST) and safety, in this case considering the number and proportion of subjects with treatment TEAEs (any grade) . In addition, the changes in the tumor microenvironment induced by the injection of BO-112 will be also evaluated as exploratory endpoints.
Conditions
- Colorectal Cancer
- Gastric Cancer
- Oesophageal Cancer
Interventions
Hepatic BiopsyProcedure
In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.
BO-112 with pembrolizumabDrug
BO-112 was administered in the liver metastasis at the dose of 1mg (1.2 mL) in combination with intravenous pembrolizumab given at the fixed dose of 200 mg, every 3 weeks for up to 35 cycles (2 years). During the first cycle, BO-112 was administered on D1 and D8.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anti-tumour Efficacy:Overall Response Rate (ORR) Based on RECIST 1.1Time frame: from baseline to approximately 8 months
- Safety: Adverse EventsTime frame: from baseline to approximately 8 months
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Institut Jules Bordet
Brussels, Belgium
UCL St-Luc
Brussels, Belgium
University Hospital Antwerp (UZA)
Edegem, Belgium
Universitair Ziekenhus Gent
Ghent, Belgium
IRCCS Ospedale Policlinico San Martino
Genova, Italy
Azienda Ospedaliera Ospedale Niguarda Ca'Granda
Milan, Italy
Hospital Valle Hebrón
Barcelona, Spain
Hospital Gregorio Marañón
Madrid, Spain
Hospital Ramón y Cajal
Madrid, Spain
Clínica Universitaria de Navarra
Pamplona, Spain
Hospital Clínico de Valencia
Valencia, Spain
Hospital Reina Sofía
Córdoba, Cordoba, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.